Newsletter
Sign up for the Fund's newsletter and get the lastest news, calls and events
| Titel Sort descending | Periode | Program | |
|---|---|---|---|
| Talegenkendelse hjælper børn med at lære at læse og skaber nye interaktive læseoplevelser | 2016 - 2017 | Innobooster
|
|
|
Talegenkendelse hjælper børn med at lære at læse og skaber nye interaktive læseoplevelser
Period
2016 - 2017
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
30.97 Invested
458.400 Budget
1.5 mill. Partners
Knowlge ApS People
Maneno ApS
Read more about the project
| |||
| Talenthub Navigator | 2021 - 2022 | Innobooster
|
|
|
Talenthub Navigator
Period
2021 - 2022
Region
Region Nordjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
31.16 Invested
434.362 Budget
1.4 mill. Partners
TalentHub.io A/S People
TalentHub.io A/S
Read more about the project
| |||
| Talkherd: AI-understøttet moderation af verbale angreb | 2022 - 2023 | Innobooster
|
|
|
Talkherd: AI-understøttet moderation af verbale angreb
Period
2022 - 2023
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
998.900 Budget
2.9 mill. Partners
Analyse Og Tal FMBA People
ANALYSE OG TAL F.M.B.A
Read more about the project
| |||
| Talking Ninja 3, Maj 2017 | 2017 - 2019 | Innobooster
|
|
|
Talking Ninja 3, Maj 2017
Period
2017 - 2019
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33.07 Invested
487.812 Budget
1.5 mill. Partners
Talking Ninja IVS People
Talking Ninja IVS
Read more about the project
| |||
| Talmo Genkendelse Af Reservedele Med Kunstig Intelligens | 2018 - 2018 | Innobooster
|
|
|
Talmo Genkendelse Af Reservedele Med Kunstig Intelligens
Period
2018 - 2018
Region
Region Nordjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
10.46 Invested
131.225 Budget
1.3 mill. Partners
Talmo People
Talmo ApS
Read more about the project
| |||
| Tandsundhed og machine learning | 2019 - 2020 | Innobooster
|
|
|
Tandsundhed og machine learning
Period
2019 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
29.64 Invested
495.000 Budget
1.7 mill. Partners
Adent ApS People
Adent ApS
Read more about the project
| |||
| Tange & Partners i Vækstsporet | 2018 - 2019 |
|
|
|
Tange & Partners i Vækstsporet
Period
2018 - 2019
Region
Region Syddanmark Program
Area
Handel, Service og Samfund Investment
Percentage
100 Invested
150.000 Budget
150.000 Partners
TANGE & PARTNERS ApS People
TANGE & PARTNERS ApS
Read more about the project
| |||
| TapTraQ mobilapps projekt | 2016 - 2017 | Innobooster
|
|
|
TapTraQ mobilapps projekt
Period
2016 - 2017
Region
Region Nordjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
162.112 Budget
491.250 Partners
TapTraQ ApS People
TapTraQ ApS
Read more about the project
| |||
| Target discovery using machine learning approaches in cardiometabolic disease | 2021 - 2024 | Industrial Researcher
|
|
|
Target discovery using machine learning approaches in cardiometabolic disease
Period
2021 - 2024
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
48.88 Invested
1.2 mill. Budget
2.5 mill. Partners
University of Copenhagen, Novo Nordisk A/S People
Novo Nordisk A/S
Read more about the project
| |||
| Target identification platform for discovery of receptors for orphan ligands | 2020 - 2023 | Industrial Researcher
|
|
|
Target identification platform for discovery of receptors for orphan ligands
Period
2020 - 2023
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
1.1 mill. Budget
1.1 mill. Partners
Københavns Universitet, Novo Nordisk A/S - E1 People
Novo Nordisk A/S - E1
Read more about the project
| |||
| TARGET – Therapeutic Aptamer-Reformulated Glioblastoma Treatment | 2025 - 2026 | Innoexplorer
|
|
|
TARGET – Therapeutic Aptamer-Reformulated Glioblastoma Treatment
Period
2025 - 2026
Region
Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
Danmarks Tekniske Universitet People
Danmarks Tekniske Universitet
Read more about the project
| |||
| Targeted Auger radiotherapy: A new drug class to cure glioblastoma | 2021 - 2022 | Innoexplorer
|
|
|
Targeted Auger radiotherapy: A new drug class to cure glioblastoma
Period
2021 - 2022
Region
Region Hovedstaden Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
Danmarks Tekniske Universitet People
Danmarks Tekniske Universitet
Read more about the project
| |||
| Targeted Multiple Sclerosis therapy using a novel genetically engineered innate immune cell differentiated from pluripotent stem cells | 2024 - 2027 | Industrial Researcher
|
|
|
Targeted Multiple Sclerosis therapy using a novel genetically engineered innate immune cell differentiated from pluripotent stem cells
Period
2024 - 2027
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
39.78 Invested
1.1 mill. Budget
2.7 mill. Interferon beta (IFNb) var det første godkendte lægemiddel til behandling af den neurodegenerative sygdom Multipel Sklerose. Denne og andre aktuelle behandlinger har dog en række bivirkninger. Vi vil udvikle en celleterapi baseret på plasmacytoide dendritcellers (pDC'er) unikke immun-regulerende evner. Det vil vi gøre ved at producere pDC'er fra stamceller og genetisk manipulere disse til at producere og frigive IFNb lokalt efter binding til et specifikt antigen på demyelinerede neuroner.
Partners
Aarhus University, UNIKUM Therapeutics ApS People
Read more about the project
| |||
| Targeting adenylate cyclase 3 (ADCY3) to promote anorexigenic signaling in the treatment of obesity | 2020 - 2023 | Industrial Researcher
|
|
|
Targeting adenylate cyclase 3 (ADCY3) to promote anorexigenic signaling in the treatment of obesity
Period
2020 - 2023
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
1.1 mill. Budget
1.1 mill. Partners
University of Copenhagen, Novo Nordisk A/S - G8, x9 m.fl. People
Novo Nordisk A/S - G8, x9 m.fl.
Read more about the project
| |||
| Targeting breast cancer associated HERV-K: Finalizing clinical regimen and prognosticators for clinical studies | 2020 - 2023 | Industrial Researcher
|
|
|
Targeting breast cancer associated HERV-K: Finalizing clinical regimen and prognosticators for clinical studies
Period
2020 - 2023
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
1.2 mill. Budget
1.2 mill. Partners
University of Copenhagen, INPROTHER ApS People
INPROTHER ApS
Read more about the project
| |||